Bivin & Associates’s Novo Nordisk NVO Stock Holding History

Bivin & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	-$1K	–	403
2021 Q4	$1K	Buy	+10	New	+$542	﹤0.01%	344

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Bivin & Associates's NVO Position: Q1 2022 in Review

Bivin & Associates sold out of Novo Nordisk (NVO) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Bivin & Associates first reported a position in NVO in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 903 funds tracked by Wall St. Rank hold NVO as of Q1 2022.

Bivin & Associates reported no remaining Novo Nordisk position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 10 Novo Nordisk shares in Q1 2022, an estimated $1K.
Bivin & Associates first reported a position in Novo Nordisk in Q4 2021 and held it in 1 quarter.
Bivin & Associates's Novo Nordisk position peaked at $1K in Q4 2021.
903 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.